/ALX

Alexander's Inc

ALX

$249.18USD↓-1.63%-4.12 today

MARKET CAP

1.3B

P/E (TTM)

62.1x

FWD P/E

—

DAY RANGE

$246 – $255

52W RANGE

$201

$289

AI Summary

Stalk

TrimMedium

ALX is trading below key short-term EMAs after breaking the $259 support on heavy volume, confirming bearish medium-term momentum. Price is extended and deeply oversold, so selling now risks poor execution into a relief bounce. Selling should be deferred until a rebound into the 259–264 EMA resistance zone. The long-term trend remains bullish as long as the rising 200-day SMA holds.

↑Evorpacept and ALX2004 trials tracking for registrational studies by mid-2027.
↑Earnings yield ~22% indicates resource efficiency and possible undervaluation.
↓Weak balance sheet quality raises funding concerns for ongoing trials.

Full analysis →

Buying

3

institutions

Selling

6

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	229.59 K	63.27 M	+10.96 K	+22.5%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	20.62 K	5.68 M	+-4.90 K	-5.7%	0.01%
JC Jpmorgan Chase & Co Q2 2026	SELL	19.81 K	5.60 M	+-13.00	+19.3%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	15.40 K	4.24 M	+1.14 K	+26.0%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUY	10.04 K	2.37 M	+5.41 K	+135.0%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	1.60 K	442.00 K	+-8.94 K	-82.3%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	873.00	240.56 K	+-5.00 K	-82.7%	0.00%
HS Hussman Strategic Advisors, Inc. Q2 2026	SELL	0.00	0.00	+-6.30 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-850.00	-100.0%	0.00%